Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibolone and raloxifene versus placebo in late postmenopausal women aged 70 years or older
NL-OMON23828Active, not recruiting
- Sponsor
- dr HJJ Verhaar
- Start
- Jul 2003
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Sarcopenia and osteopenia comparing Tibolone plus placebo, Evista plus placebo and Double placebo (3 arms). Primary endpoints: Maximum voluntary isometric knee extension strength at 24 months, Explosive leg extensor power at 24 months and 3 more. Started Jul 2003; status: active, not recruiting.
02
Drugs
tiboloneraloxifene
03
Conditions
Sarcopeniaosteopenia
Beyond the preview
Go deeper on NL-OMON23828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23828.